Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04939701
Other study ID # 0739-CL-0101
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date January 11, 2022
Est. completion date June 1, 2023

Study information

Verified date November 2023
Source Astellas Pharma Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, and tolerability of ASP0739, when administered as a single agent and in combination with pembrolizumab. This study will also evaluate the clinical response and other measures of anticancer activity of ASP0739 when administered as a single agent and in combination with pembrolizumab based on central and local assessment.


Description:

The study is comprised of 2 phases. Phase 1 (dose escalation) includes participants with solid tumors known to express New York esophageal squamous cell carcinoma 1 (NY-ESO-1). Phase 2 (ASP0739 as single agent and in combination with pembrolizumab) includes participants with relapsed/refractory Synovial Sarcoma (SS), myxoid/round cell liposarcoma (MRCL), and ovarian cancer who have not responded to Standard of Care (SOC) or are ineligible for standard therapy. Phase 2 single agent will also include a cohort of participants with select solid tumors known to express NY-ESO-1 (melanoma, Non Small Cell Lung Cancer-adenocarcinoma [NSCLC], squamous cell and esophageal squamous cell carcinoma [ESCC]). Japanese participants will only be enrolled into the monotherapy arm of the dose expansion cohort.


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date June 1, 2023
Est. primary completion date June 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Phase 1 Dose Escalation only: - Participant has relapsed/refractory (R/R) solid tumor known to express NY-ESO-1 after completing available Standard of Care (SOC) therapy or is not a candidate for SOC therapy. NY-ESO-1 expression status is not required for participant entry. Safety Lead-in, Phase 2 Single agent and Combination Therapy only: - Participant has relapsed/refractory (R/R) synovial sarcoma (SS) or myxoid/round cell liposarcoma (MRCL) disease after undergoing available SOC treatment or is not a candidate for SOC therapy (must have previously received either an anthracycline or ifosfamide containing regimen or another systemic regimen, if not a candidate for either agent). - Participant has not received prior checkpoint inhibitor therapy (i.e., Programmed Cell Death Protein 1 [PD-1]/Programmed Death Ligand 1 [PD-L1] treatment naive) - SS: confirmation by the presence of a translocation between SYT on the X chromosome and SSX1, SSX2, or SSX4 on chromosome 18 (may be presented in the pathology report as t [X;18]). - MRCL: confirmation by the presence of the reciprocal chromosomal translocation t (12;16) (q13;p11) or t(12;22)(q13;q12). - Participant has R/R ovarian cancer that is: - platinum resistant OR platinum-sensitive, but the participant is not a candidate for platinum or other SOC therapy. - Participant has not received prior checkpoint inhibitor therapy (i.e., naive PD-1/PD-L1 treatment participants). - Participant has R/R solid tumor (melanoma, non-small cell lung cancer [NSCLC]-adenocarcinoma and squamous cell, or esophageal squamous cell carcinoma [ESCC]) after available SOC treatment or is not a candidate for SOC therapy (single-agent only). - Participant consents to provide an archival tumor specimen in a tissue block or unstained serial slides prior to IP administration. - Participant in phase 2 consents to provide tumor specimen obtained within 56 days prior to first dose of study treatment, as tissue block or unstained serial slides. - Participant in phase 2 consents to undergoing a tumor biopsy (core needle biopsy or excision) during the treatment period. - Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of <= 2. - Participant with life expectancy of >= 12 weeks at the time of screening. - Participant must meet criteria for clinical laboratory tests during screening period. - A female participant is eligible to participate if she is not pregnant and at least one of the following conditions apply: - Not a woman of childbearing potential (WOCBP) OR - WOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for at least 6 months after the final investigational product (IP) administration. - Female participant must not be breastfeeding at screening or during the study period and for 6 months after the final IP administration. - Female participant must not donate ova at screening and throughout the study period and for 6 months after the final IP administration. - A male participant with female partner(s) of childbearing potential must agree to use contraception during the treatment period and for at least 6 months after the final IP administration. - Male participant must not donate sperm starting at screening and throughout the study period and for 6 months after the final IP administration. - Participant agrees not to participate in another interventional study while on treatment. - Participant measurable disease according to RECIST 1.1. For participant with only 1 measurable lesion and prior radiotherapy, the lesion must be outside the field of prior radiotherapy or must have documented progression following radiation therapy. Exclusion Criteria: - Participant has persistent non-hematological toxicities of >= grade 2 (National Cancer Institute's Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 5.0), with symptoms and objective findings from treatment (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, radiation or surgery). - Participant has received any of the following therapies (for inclusion in the study, all abnormalities must have returned to <= grade 1): - Systemic immunomodulators (checkpoint inhibitors)-except the dose escalation phase and the NY-ESO-1 solid tumor (melanoma, NSCLC-adenocarcinoma and squamous cell and ESCC) cohorts in the dose expansion phase of monotherapy, which may have received prior checkpoint inhibitor therapy - Immunosuppressive drugs including steroids <= 14 days prior to treatment - Cytotoxic agents <= 14 days prior to treatment - Investigational agent <= 21 days prior to treatment or 5 half-lives, whichever is shorter - Radiation therapy <= 21 days prior to treatment - Participant has clinically active or untreated nervous system metastases. Participants with previously treated Central Nervous System (CNS) metastases are eligible, if they are clinically stable and have no evidence of CNS progression by imaging for at least 4 weeks prior to start of study treatment and are not requiring immunosuppressive doses of systemic steroids (> 30 mg per day of hydrocortisone or > 10 mg per day of prednisone or equivalent) for longer than 2 weeks. - Participant has an active autoimmune disease. Participant with type 1 diabetes mellitus, endocrinopathies stably maintained on appropriate replacement therapy, or skin disorders (e.g., vitiligo, psoriasis, or alopecia) not requiring systemic treatment are allowed. - Participant was discontinued from prior immunomodulatory therapy due to a grade >= 3 toxicity that was mechanistically related (e.g., immune related) to the agent. - Participant has known history of serious hypersensitivity reaction to a known ingredient of ASP0739 or pembrolizumab or severe hypersensitivity reaction to treatment with another monoclonal antibody. - Participant has a prior malignancy active (i.e., requiring treatment or intervention) within the previous 2 years prior to screening visit, except for locally curable malignancies that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast. - Participant has received a prior allogeneic bone marrow or solid organ transplant. - Participant has an active uncontrolled infection within 14 days of treatment. - Participant is known to have human immunodeficiency virus infection. - Participant has active hepatitis B or C or other active hepatic disorder or participant is on hepatitis treatment. Hepatitis C RNA testing is not required in participants with negative hepatitis C antibody testing. - Participant has any condition which makes the participant unsuitable for study participation. - Participant has had a major surgical procedure and has not completely recovered within 28 days prior to the start of study treatment. - Participant has had a myocardial infarction or unstable angina within 6 months prior to the start of study treatment or currently has an uncontrolled illness including, but not limited to, symptomatic congestive heart failure, clinically significant cardiac disease, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - Participant is expected to require another form of anti-cancer therapy while on study treatment. - Participant has a known or suspected hypersensitivity to bovine-derived protein or has suspected hypersensitivity to any ingredients of ASP0739. Additional Exclusion Criteria for Participants in Combination Therapy Cohorts - Participants with a history of myocarditis or congestive heart failure (as defined by New York Heart Associated Functional Classification III or IV), as well as unstable angina, serious uncontrolled cardiac arrhythmia, uncontrolled infection, or myocardial infarction 6 months prior to study entry. - Participants with active interstitial lung disease (ILD)/pneumonitis or a history of ILD/pneumonitis requiring treatment with systemic steroids. - Participants with baseline pulse oximetry < 92% "on Room air." - Participants must not have known microsatellite instability-high or deficient MisMatch Repair.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ASP0739
Intravenous (IV)
Pembrolizumab
Intravenous (IV)

Locations

Country Name City State
United States Northwestern University Robert H. Lurie Comprehensive Cancer Center Chicago Illinois
United States The University of Chicago Medicine Chicago Illinois
United States City of Hope Duarte California
United States University of Miami Miami Florida
United States NYU Perlmutter Cancer Center New York New York
United States Brown University Providence Rhode Island

Sponsors (1)

Lead Sponsor Collaborator
Astellas Pharma Global Development, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Dose Limiting Toxicities (DLTs) for ASP0739 Single Agent A DLT is defined as any of the following occurring within 28 days of the first dose on cycle 1 day 1 (C1D1) considered related to IP.
Grade (Gr) = 2 autoimmune reaction; Gr 3 immune-related adverse events (irAEs) not resolving to Gr = 1 in 3-5 days; Gr 4 irAEs; Gr = 3 non-hematological AEs not resolving to Gr = 2 within 72 hours of onset; Gr 4 neutropenia; Gr 3 febrile neutropenia; Gr 4 thrombocytopenia; Gr 3 anemia/thrombocytopenia with transfusion; Gr 4 anemia; aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 5 x upper limit of normal (ULN) (Gr = 3) without liver metastases; AST/ALT > 8 x ULN with liver metastases; Confirmed Hy's Law; Gr = 3 liver function test (LFT) abnormality; Gr 5 toxicity; > 2 week delay in cycle 2 due to treatment-related toxicity.
28 days
Primary Incidence of Dose Limiting Toxicities (DLTs) for ASP0739 + Pembrolizumab Safety Lead-in A DLT is defined as any of the following occurring within 28 days of the first dose on C1D1 considered related to IP.
Gr = 2 autoimmune reaction; Gr 3 irAEs not resolving to Gr = 1 in 3-5 days; Gr 4 irAEs; Gr = 3 non-hematological AEs not resolving to Gr = 2 within 72 hours of onset; Gr 4 neutropenia; Gr 3 febrile neutropenia; Gr 4 thrombocytopenia; Gr 3 anemia/thrombocytopenia with transfusion; Gr 3 thrombocytopenia with hospitalization; Gr 4 anemia; AST/ALT > 5 x ULN (Gr = 3) without liver metastases; AST/ALT > 8 x ULN with liver metastases; Confirmed Hy's Law; Total Bilirubin > 3 x ULN (Gr = 3); Gr = 3 LFT abnormality; Gr 5 toxicity; > 2 week delay in cycle 2 due to treatment-related toxicity; Gr = 2 pneumonitis; Gr = 2 encephalopathy, meningitis, motor/sensory neuropathy; Guillain-Barre syndrome/myasthenic syndrome/myasthenia gravis; Infusion-related reaction requiring infusion discontinuation.
28 days
Primary Number of Participants with adverse events (AEs) An AE is any untoward medical occurrence in a participant temporally associated with the use of study IP, whether or not considered related to the study IP, and other study treatments. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study IP and other study treatments. This includes events related to the comparator and events related to the (study) procedures. AEs will be graded using NCI-CTCAE version 5.0. Up to 27 months
Primary Number of Participants with Serious Adverse Events (SAEs) An AE is considered "serious" if the event results in death; is life threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in congenital anomaly/birth defect; other medically important events. Up to 27 months
Primary Number of participants with laboratory value abnormalities and/or AEs Number of participants with potentially clinically significant laboratory values. Up to 27 months
Primary Number of participants with 12-lead electrocardiogram (ECG) abnormalities and/or AEs Number of participants with potentially clinically significant 12-lead ECG values. Up to 27 months
Primary Number of participants with vital sign abnormalities and/or AEs Number of participants with potentially clinically significant vital sign values. Up to 27 months
Primary Number of participants with physical exam abnormalities and/or AEs Number of participants with potentially clinically significant physical exam values. Up to 27 months
Primary Number of participants at each grade of the Eastern Cooperative Oncology Group (ECOG) performance status The ECOG scale will be used to assess performance status. Grades range from 0 (fully active) to 5 (dead). Negative change scores indicate an improvement. Positive scores indicate a decline in performance. Up to 27 months
Primary Objective Response Rate per Immune Response Evaluation Criteria in Solid Tumors (iRECIST) (iORR) by Independent Central Review iORR is defined as the proportion of participants for each dose level whose best overall response is rated as confirmed Complete Response (iCR) or Partial Response (iPR) per iRECIST by Independent Central Review. Up to 36 months
Secondary Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 ORR is defined as the proportion of participants for each dose level whose best overall response is rated as Complete Response (CR) or Partial Response (PR) per RECIST v1.1. Up to 36 months
Secondary Disease Control Rate per iRECIST (iDCR) iDCR is defined as the proportion of participants for each dose level whose best overall response is rated as confirmed iCR, iPR or stable disease (SD), per iRECIST. Up to 36 months
Secondary Disease Control Rate per RECIST v1.1 (DCR) DCR is defined as the proportion of participants for each dose level whose best overall response is rated as confirmed CR, PR or stable disease (SD), per RECIST v1.1. Up to 36 months
Secondary Progression-Free Survival per iRECIST (iPFS) by Independent Central Review iPFS is defined as the time from the start of the study treatment until death from any cause or radiographic disease progression assessed per iRECIST, whichever comes first, as assessed by Independent Central Review. Up to 36 months
Secondary iPFS per iRECIST by local assessment iPFS is defined as the time from the start of the study treatment until death from any cause or radiographic disease progression assessed per iRECIST, whichever comes first, as assessed by local assessment. Up to 36 months
Secondary Progression-Free Survival per RECIST v1.1 (PFS) by Independent Central Review PFS is defined as the time from the start of the study treatment until death from any cause or radiographic disease progression assessed per RECIST v1.1, whichever comes first, as assessed by independent central review. Up to 36 months
Secondary PFS per RECIST v1.1 by local assessment PFS is defined as the time from the start of the study treatment until death from any cause or radiographic disease progression assessed per RECIST v1.1, whichever comes first, as assessed by local assessment. Up to 36 months
Secondary Duration of Overall Survival (OS) OS is defined as the time from the date of first dose until the date of death from any cause. Up to 36 months
Secondary Duration of Response per iRECIST (iDOR) by Independent Central Review iDOR will be calculated only for the subgroup of participants with confirmed response iCR/iPR per iRECIST, as assessed by Independent Central Review. Up to 36 months
Secondary iDOR per iRECIST by local assessment iDOR will be calculated only for the subgroup of participants with confirmed response iCR/iPR per iRECIST, as assessed by local assessment. Up to 36 months
Secondary Duration of Response per RECIST (DOR) v1.1 by Independent Central Review DOR will be calculated only for the subgroup of participants with confirmed response CR/PR per RECIST v1.1, as assessed by Independent Central Review. Up to 36 months
Secondary DOR per RECIST v1.1 by local assessment DOR will be calculated only for the subgroup of participants with confirmed response CR/PR per RECIST v1.1, as assessed by local assessment. Up to 36 months
Secondary ORR per iRECIST (iORR) by local assessment iORR is defined as the proportion of participants for each dose level whose best overall response is rated as confirmed iCR or iPR, by local assessment. Up to 36 months
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2